clenbuterol has been researched along with Cardiac Failure in 16 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clenbuterol was well tolerated and led to a significant increase in both lean mass and the lean/fat ratio." | 6.73 | Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. ( George, I; Kamalakkannan, G; LaManca, J; Mancini, DM; Maybaum, S; McLaughlin, BT; Petrilli, CM; Shane, E, 2008) |
| "Clenbuterol treatment improved in vivo LV function measured with echocardiography (LVEF (%): HF 35." | 5.35 | Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. ( Barton, PJ; Felkin, LE; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH; Youssef, S, 2008) |
| "Clenbuterol (Cl), a β2 agonist, is associated with enhanced myocardial recovery during left ventricular assist device (LVAD) support, and exerts beneficial remodelling effects during mechanical unloading (MU) in rodent heart failure (HF)." | 3.80 | Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading. ( Gandhi, A; Ibrahim, M; Kukadia, P; Navaratnarajah, M; Shah, A; Siedlecka, U; Soppa, G; Terracciano, CM; van Doorn, C; Yacoub, MH, 2014) |
| "Clenbuterol, a compound classified as a beta2-adrenoceptor (AR) agonist, has been employed in combination with left ventricular assist devices (LVADs) to treat patients with severe heart failure." | 3.74 | Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes. ( Arora, M; Harding, SE; Kolettis, T; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH, 2008) |
| "Clenbuterol was well tolerated and led to a significant increase in both lean mass and the lean/fat ratio." | 2.73 | Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. ( George, I; Kamalakkannan, G; LaManca, J; Mancini, DM; Maybaum, S; McLaughlin, BT; Petrilli, CM; Shane, E, 2008) |
| "Heart failure is a widespread condition in the United States that is predicted to significantly increase in prevalence in the next decade." | 2.61 | Left ventricular assist device recovery: does duration of mechanical support matter? ( Chaparro, SV; Pham, BN, 2019) |
| "The examination of the heart showed left ventricular hypertrophy, while the right coronary artery showed only a small vascular lumen (3 mm in diameter), due to its anatomical structure." | 1.51 | Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone). ( Andresen-Streichert, H; Geyer, H; Glenewinkel, F; Juebner, M; Lehmann, S; Rothschild, MA; Schiwy-Bochat, KH; Thevis, M; Thomas, A, 2019) |
| "Clenbuterol treatment improved in vivo LV function measured with echocardiography (LVEF (%): HF 35." | 1.35 | Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure. ( Barton, PJ; Felkin, LE; Lee, J; Siedlecka, U; Soppa, GK; Stagg, MA; Terracciano, CM; Yacoub, MH; Youssef, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lehmann, S | 1 |
| Thomas, A | 1 |
| Schiwy-Bochat, KH | 1 |
| Geyer, H | 1 |
| Thevis, M | 1 |
| Glenewinkel, F | 1 |
| Rothschild, MA | 1 |
| Andresen-Streichert, H | 1 |
| Juebner, M | 1 |
| Pham, BN | 1 |
| Chaparro, SV | 1 |
| Tanaka, TD | 1 |
| Lancaster, JJ | 1 |
| Juneman, E | 1 |
| Bahl, JJ | 1 |
| Goldman, S | 1 |
| Pokorný, M | 1 |
| Cervenka, L | 1 |
| Netuka, I | 1 |
| Pirk, J | 1 |
| Koňařík, M | 1 |
| Malý, J | 1 |
| Navaratnarajah, M | 1 |
| Siedlecka, U | 3 |
| Ibrahim, M | 1 |
| van Doorn, C | 1 |
| Soppa, G | 1 |
| Gandhi, A | 1 |
| Shah, A | 1 |
| Kukadia, P | 1 |
| Yacoub, MH | 7 |
| Terracciano, CM | 3 |
| Habedank, D | 1 |
| Steeg, M | 1 |
| Anker, SD | 1 |
| Arora, M | 1 |
| Kolettis, T | 1 |
| Soppa, GK | 2 |
| Lee, J | 2 |
| Stagg, MA | 2 |
| Harding, SE | 1 |
| Maybaum, S | 2 |
| Birks, EJ | 3 |
| George, RS | 1 |
| Hedger, M | 1 |
| Bahrami, T | 1 |
| Wilton, P | 1 |
| Bowles, CT | 1 |
| Webb, C | 1 |
| Bougard, R | 1 |
| Amrani, M | 1 |
| Dreyfus, G | 1 |
| Khaghani, A | 2 |
| Mitra, MS | 1 |
| Schilling, JD | 1 |
| Wang, X | 1 |
| Jay, PY | 1 |
| Huss, JM | 1 |
| Su, X | 1 |
| Finck, BN | 1 |
| Kassner, A | 1 |
| Toischer, K | 1 |
| Bohms, B | 1 |
| Kolkhof, P | 1 |
| Abraham, G | 1 |
| Hasenfuβ, G | 1 |
| Morshuis, M | 1 |
| Schulte Eistrup, S | 1 |
| El-Banayosy, A | 1 |
| Gummert, J | 1 |
| Milting, H | 1 |
| Hon, JK | 1 |
| Barton, PJ | 3 |
| Felkin, LE | 2 |
| Cullen, ME | 1 |
| Banner, NR | 2 |
| Grindle, S | 2 |
| Hall, JL | 2 |
| Miller, LW | 2 |
| Latif, N | 1 |
| Hardy, JP | 1 |
| Rider, JE | 1 |
| Youssef, S | 1 |
| Kamalakkannan, G | 1 |
| Petrilli, CM | 1 |
| George, I | 1 |
| LaManca, J | 1 |
| McLaughlin, BT | 1 |
| Shane, E | 1 |
| Mancini, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy[NCT01942590] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 18
| Intervention | meters (Mean) |
|---|---|
| Clenbuterol | 18.09 |
| Placebo Comparator | 6.878 |
Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 52
| Intervention | meters (Mean) |
|---|---|
| Clenbuterol | 16.42 |
| Placebo Comparator | -18.13 |
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 18
| Intervention | change in FVC measured as % expected (Mean) |
|---|---|
| Clenbuterol | 1.575 |
| Placebo Comparator | 2.825 |
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 52
| Intervention | change in FVC measured as % expected (Mean) |
|---|---|
| Clenbuterol | -5.738 |
| Placebo Comparator | 7.775 |
(NCT01942590)
Timeframe: Baseline, Week 52
| Intervention | mmol/mol CN (Mean) |
|---|---|
| Clenbuterol | -1.1 |
| Placebo Comparator | -1.667 |
The Glc4 biomarker is measured in urine and correlates with muscle glycogen content. It is a noninvasive measurement that serves as a biomarker for Pompe disease. (NCT01942590)
Timeframe: Baseline, Week 18
| Intervention | mmol/mol CN (Mean) |
|---|---|
| Clenbuterol | -1.733 |
| Placebo Comparator | 0.0667 |
Liver toxicity, as defined by a >3x increase in AST or ALT from the respective baseline values and/or an increase in direct, indirect or total bilirubin of >3x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52
| Intervention | participants (Number) |
|---|---|
| Clenbuterol | 0 |
| Placebo Comparator | 0 |
Worsening muscle involvement, as defined by >3x increase in CK from baseline that is >2x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52
| Intervention | participants (Number) |
|---|---|
| Clenbuterol | 1 |
| Placebo Comparator | 0 |
The GSGC is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 4 components: Gait, Climbing Stairs, Gower's Manuever, Arising From a Chair. Lowest score 4 = normal muscle function, highest score 27 = unable to perform motor function tests. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 17 | 15.14 | 13.8 |
| Placebo Comparator | 7.5 | 6.5 | 6.5 |
The Late-Life Function & Disability Instrument (Late-Life FDI) is an evaluative outcome instrument for community-dwelling older adults. Highest score 240 = normal function and no disability, lowest score 0 = low levels of frequency of participating in life tasks. (NCT01942590)
Timeframe: Baseline, Week 18, Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 103.75 | 106.7 | 112.5 |
MEP reflects the strength of the abdominal muscles and other expiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | percentage of MEP (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 40.4 | 40 | 53.9 |
| Placebo Comparator | 62.8 | 83.3 | 49.2 |
MIP is a measurement of inspiratory muscle weakness, including weakness of the diaphragm. MIP is decreased in Pompe disease and reflects weakness of respiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | percentage of MIP (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 56.3 | 47.4 | 68.5 |
| Placebo Comparator | 96.8 | 83.8 | 104.6 |
The QMFT is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 16 motor function tests. Lowest score 0 = unable to perform motor function tests, highest score 64 = normal muscle function. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Week 18 | Week 52 | |
| Clenbuterol | 35 | 40.6 | 46.5 |
| Placebo Comparator | 53.75 | 54.75 | 56.25 |
3 reviews available for clenbuterol and Cardiac Failure
| Article | Year |
|---|---|
Left ventricular assist device recovery: does duration of mechanical support matter?
Topics: Adult; Atrophy; Calcium; Cardiomyopathy, Dilated; Clenbuterol; Female; Heart; Heart Failure; Heart T | 2019 |
Ventricular assist devices in heart failure: how to support the heart but prevent atrophy?
Topics: Adrenergic beta-Agonists; Animals; Atrophy; Clenbuterol; Heart Failure; Heart-Assist Devices; Humans | 2014 |
Bridge to recovery with the use of left ventricular assist device and clenbuterol.
Topics: Adrenergic beta-Agonists; Clenbuterol; Heart Failure; Heart-Assist Devices; Humans | 2003 |
1 trial available for clenbuterol and Cardiac Failure
| Article | Year |
|---|---|
Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure.
Topics: Adrenergic beta-Agonists; Adult; Body Composition; Chronic Disease; Clenbuterol; Double-Blind Method | 2008 |
12 other studies available for clenbuterol and Cardiac Failure
| Article | Year |
|---|---|
Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone).
Topics: Adult; Anabolic Agents; Androstanols; Clenbuterol; Clomiphene; Coronary Vessels; Doping in Sports; F | 2019 |
Clenbuterol plus granulocyte colony-stimulating factor regulates stem/progenitor cell mobilization and exerts beneficial effect by increasing neovascularization in rats with heart failure.
Topics: Animals; Clenbuterol; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Heart Failur | 2013 |
Impact of combined clenbuterol and metoprolol therapy on reverse remodelling during mechanical unloading.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Calcium; Clenb | 2014 |
Clenbuterol impairs muscle quality and is potentially dangerous.
Topics: Adrenergic beta-Agonists; Clenbuterol; Heart Failure; Humans; Muscle Strength; Muscle Weakness; Musc | 2008 |
Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albuterol; Animals; Calcium Channels, L-Type; | 2008 |
Cardiac recovery during continuous-flow left ventricular assist device support: some good news from across the Atlantic.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Cardiomyopathies; Clenbuterol; Clinical Protocols; Clin | 2011 |
Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study.
Topics: Adult; Cardiomyopathy, Dilated; Cardiovascular Agents; Clenbuterol; Female; Heart Failure; Heart-Ass | 2011 |
Cardiac lipin 1 expression is regulated by the peroxisome proliferator activated receptor γ coactivator 1α/estrogen related receptor axis.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Animals, Newborn; Cells, Cultured; Chromatin Immunopre | 2011 |
Regulation of cyclic adenosine monophosphate release by selective β2-adrenergic receptor stimulation in human terminal failing myocardium before and after ventricular assist device support.
Topics: Adenylyl Cyclases; Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; B | 2012 |
Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Cardiomyopathy, Dilated; Chemokine CX | 2005 |
Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Cardiomyopathies; Cardiovascul | 2005 |
Role and possible mechanisms of clenbuterol in enhancing reverse remodelling during mechanical unloading in murine heart failure.
Topics: Actin Cytoskeleton; Action Potentials; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists | 2008 |